TW202034900A - 有關耳用治療劑之醫藥組成物及方法 - Google Patents

有關耳用治療劑之醫藥組成物及方法 Download PDF

Info

Publication number
TW202034900A
TW202034900A TW108135698A TW108135698A TW202034900A TW 202034900 A TW202034900 A TW 202034900A TW 108135698 A TW108135698 A TW 108135698A TW 108135698 A TW108135698 A TW 108135698A TW 202034900 A TW202034900 A TW 202034900A
Authority
TW
Taiwan
Prior art keywords
composition
poloxamer
specific embodiments
pharmaceutically acceptable
concentration
Prior art date
Application number
TW108135698A
Other languages
English (en)
Chinese (zh)
Inventor
雷賈許 曼查達
斯內哈爾 奇德卡
理查德 斯仲二世
艾斯利 班克斯
布拉德里 泰特
克里斯托弗 路司
威爾 麥克廉
Original Assignee
美商頻率醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商頻率醫療公司 filed Critical 美商頻率醫療公司
Publication of TW202034900A publication Critical patent/TW202034900A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108135698A 2018-10-02 2019-10-02 有關耳用治療劑之醫藥組成物及方法 TW202034900A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739933P 2018-10-02 2018-10-02
US62/739,933 2018-10-02

Publications (1)

Publication Number Publication Date
TW202034900A true TW202034900A (zh) 2020-10-01

Family

ID=68296763

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108135698A TW202034900A (zh) 2018-10-02 2019-10-02 有關耳用治療劑之醫藥組成物及方法

Country Status (10)

Country Link
US (1) US20220192984A1 (https=)
EP (1) EP3860562A1 (https=)
JP (1) JP2022504265A (https=)
KR (1) KR20210084484A (https=)
CN (1) CN113164381A (https=)
BR (1) BR112021006092A2 (https=)
CA (1) CA3114113A1 (https=)
MX (1) MX2021003773A (https=)
TW (1) TW202034900A (https=)
WO (2) WO2020072602A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CN113195707A (zh) * 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
KR20220007050A (ko) * 2019-04-08 2022-01-18 프리퀀시 테라퓨틱스, 인크. 난청을 치료하기 위한 chir99021과 발프로산의 조합
CN114085803B (zh) * 2020-08-24 2024-04-26 北京大学 建立具有再生特性的类器官培养体系
CA3195622A1 (en) * 2020-10-14 2022-04-21 Ear Science Institute Australia Incorporated Methods for generating inner ear hair cells
WO2022192079A1 (en) * 2021-03-08 2022-09-15 The Regents Of The University Of California Compounds for protection of noise-induced hearing-loss
EP4629989A2 (en) * 2022-12-07 2025-10-15 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
CN120053473B (zh) * 2025-04-25 2025-07-18 山东大学 赖氨酸甲基转移酶dot1l抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US447475A (en) 1891-03-03 pomerof
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
EP2854809B1 (en) 2012-06-01 2017-12-06 Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) Inhibitors of the notch signalling pathway and secretion for use in medicine
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014047391A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
EP2897947B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
CN103169649A (zh) * 2013-04-11 2013-06-26 中国人民解放军总医院 温度和离子双重敏感型原位凝胶鼻腔给药系统
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016037016A1 (en) * 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CN107075471A (zh) 2014-10-08 2017-08-18 新加坡科技研究局 将干细胞分化为肝细胞谱系的方法
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
KR102723605B1 (ko) 2015-12-22 2024-10-29 바스프 에스이 폴리에테르 블록 공중합체의 정제 방법
US10201540B2 (en) * 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
JP7012715B2 (ja) 2016-06-27 2022-01-28 エフ．ホフマン－ラ ロシュ アーゲー γ－セクレターゼモジュレーターとしてのトリアゾロピリジン
EP3481829B1 (en) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
EP3484884B1 (en) 2016-07-14 2021-01-27 Hoffmann-La Roche AG Fused pyrimidine derivatives
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
TWI757360B (zh) 2016-11-08 2022-03-11 瑞士商赫孚孟拉羅股份公司 苯氧基三唑
MX390370B (es) 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
CA3047730A1 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Quinazolinones that inhibit the formation of tau oligomers and their method of use
CA3047729A1 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
WO2018172997A1 (en) 2017-03-24 2018-09-27 Novartis Ag Isoxazole carboxamide compounds and uses thereof

Also Published As

Publication number Publication date
CA3114113A1 (en) 2020-04-09
CN113164381A (zh) 2021-07-23
BR112021006092A2 (pt) 2021-07-20
US20220192984A1 (en) 2022-06-23
MX2021003773A (es) 2021-07-16
KR20210084484A (ko) 2021-07-07
WO2020072601A1 (en) 2020-04-09
WO2020072602A1 (en) 2020-04-09
EP3860562A1 (en) 2021-08-11
JP2022504265A (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
TW202034900A (zh) 有關耳用治療劑之醫藥組成物及方法
US20220040309A1 (en) Compositions with permeation enhancers for drug delivery
ES2972205T3 (es) Pridopidina para el tratamiento del síndrome x frágil
US11162071B2 (en) Compositions and methods for generating hair cells by upregulating JAG-1
CN108024976A (zh) 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法
JP7277360B2 (ja) 薬物送達のための透過促進剤を有する組成物
US20220160664A1 (en) Taz activators and wnt agonists for treating ear disorders
US20220175776A1 (en) Combination of chir99021 and valproic acid for treating hearing loss
US20200080055A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
WO2020163814A1 (en) Compositions and methods for generating hair cells by inhibiting epigenetic targets
US20210322396A1 (en) Compositions with synergistic permeation enhancers for drug delivery
JP2022520671A (ja) 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CN116234898A (zh) 用于治疗肥胖症和代谢紊乱的Notch信号传导抑制剂